Nasdaq:US$13.50 (+0.55) | HKEX:HK$21.80 (+0.60) | AIM:£2.26 (+0.09)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)